| Guidelines for the management of transfusion dependent thalassaemia (TDT) MD Cappellini, A Cohen, J Porter, A Taher, V Viprakasit Thalassaemia International Federation, 2014 | 665 | 2014 |
| ATR-X syndrome protein targets tandem repeats and influences allele-specific expression in a size-dependent manner MJ Law, KM Lower, HPJ Voon, JR Hughes, D Garrick, V Viprakasit, ... Cell 143 (3), 367-378, 2010 | 459 | 2010 |
| A regulatory SNP causes a human genetic disease by creating a new transcriptional promoter M De Gobbi, V Viprakasit, JR Hughes, C Fisher, VJ Buckle, H Ayyub, ... Science 312 (5777), 1215-1217, 2006 | 361 | 2006 |
| Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias MD Cappellini, J Porter, A El-Beshlawy, CK Li, JF Seymour, M Elalfy, ... haematologica 95 (4), 557, 2010 | 342 | 2010 |
| Digenic inheritance of mutations in HAMP and HFE results in different types of haemochromatosis AT Merryweather-Clarke, E Cadet, A Bomford, D Capron, V Viprakasit, ... Human molecular genetics 12 (17), 2241-2247, 2003 | 317 | 2003 |
| Resistance to hepcidin is conferred by hemochromatosis-associated mutations of ferroportin H Drakesmith, LM Schimanski, E Ormerod, AT Merryweather-Clarke, ... Blood 106 (3), 1092-1097, 2005 | 310 | 2005 |
| Guidelines for the management of non transfusion dependent thalassaemia (NTDT) A Taher, E Vichinsky, K Musallam, MD Cappellini, V Viprakasit | 284 | 2014 |
| Hb H disease: clinical course and disease modifiers S Fucharoen, V Viprakasit ASH Education Program Book 2009 (1), 26-34, 2009 | 260 | 2009 |
| A phase 3 trial of luspatercept in patients with transfusion-dependent β-thalassemia MD Cappellini, V Viprakasit, AT Taher, P Georgiev, KHM Kuo, T Coates, ... New England Journal of Medicine 382 (13), 1219-1231, 2020 | 249 | 2020 |
| In vitro functional analysis of human ferroportin (FPN) and hemochromatosis-associated FPN mutations LM Schimanski, H Drakesmith, AT Merryweather-Clarke, V Viprakasit, ... Blood 105 (10), 4096-4102, 2005 | 240 | 2005 |
| Clinical classification, screening and diagnosis for thalassemia V Viprakasit, S Ekwattanakit Hematology/Oncology Clinics 32 (2), 193-211, 2018 | 235 | 2018 |
| Efficacy of deferasirox in reducing and preventing cardiac iron overload in β-thalassemia DJ Pennell, JB Porter, MD Cappellini, A El-Beshlawy, LL Chan, Y Aydinok, ... Blood, The Journal of the American Society of Hematology 115 (12), 2364-2371, 2010 | 234 | 2010 |
| A genome-wide association identified the common genetic variants influence disease severity in β0-thalassemia/hemoglobin E M Nuinoon, W Makarasara, T Mushiroda, I Setianingsih, PA Wahidiyat, ... Human genetics 127, 303-314, 2010 | 224 | 2010 |
| Changing patterns in the epidemiology of β‐thalassemia A Kattamis, GL Forni, Y Aydinok, V Viprakasit European Journal of Haematology 105 (6), 692-703, 2020 | 220 | 2020 |
| Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study AT Taher, J Porter, V Viprakasit, A Kattamis, S Chuncharunee, ... Blood, The Journal of the American Society of Hematology 120 (5), 970-977, 2012 | 170 | 2012 |
| Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major DJ Pennell, JB Porter, MD Cappellini, LL Chan, A El-Beshlawy, Y Aydinok, ... haematologica 97 (6), 842, 2012 | 156 | 2012 |
| Mutations in the general transcription factor TFIIH result in β-thalassaemia in individuals with trichothiodystrophy V Viprakasit, RJ Gibbons, BC Broughton, JL Tolmie, D Brown, P Lunt, ... Human Molecular Genetics 10 (24), 2797-2802, 2001 | 143 | 2001 |
| Evaluation of alpha hemoglobin stabilizing protein (AHSP) as a genetic modifier in patients with β thalassemia V Viprakasit, VS Tanphaichitr, W Chinchang, P Sangkla, MJ Weiss, ... Blood 103 (9), 3296-3299, 2004 | 135 | 2004 |
| A paradigm shift on beta-thalassaemia treatment: How will we manage this old disease with new therapies? MD Cappellini, JB Porter, V Viprakasit, AT Taher Blood reviews 32 (4), 300-311, 2018 | 134 | 2018 |
| Clinical features and molecular analysis in Thai patients with HbH disease V Laosombat, V Viprakasit, T Chotsampancharoen, M Wongchanchailert, ... Annals of hematology 88, 1185-1192, 2009 | 122 | 2009 |
Supachai EkwattanakitMahidol UniversityVerified email at mahidol.ac.th
